NASDAQ
43.89USD
-0.15 (-0.34%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
4.7B
P/E
—
EPS
—
Beta
0.28
52W range
13.525-48.4
Day range
42.62–45.29
Open
43.17
Prev close
44.04
Volume
373.3K
Avg volume
1.3M
Dividend
0.00
IPO
2021-03-26
https://seekingalpha.com/article/4937747-edgewise-therapeutics-the-servier-deal-creates-a-self-funded-cardiovascular-platform · 8/18/2026+1.00
https://seekingalpha.com/article/4912227-edgewise-stock-buy-on-muscular-dystrophy-program-sale-and-edg-7500-advancement · 6/5/2026+1.00
https://www.fool.com/investing/2025/12/24/why-edgewise-therapeutics-stock-rocked-the-market/ · 12/24/2025+0.90
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
